219 related articles for article (PubMed ID: 24670480)
1. Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.
Jinsmaa Y; Sullivan P; Gross D; Cooney A; Sharabi Y; Goldstein DS
Neurosci Lett; 2014 May; 569():27-32. PubMed ID: 24670480
[TBL] [Abstract][Full Text] [Related]
2. The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
Jinsmaa Y; Cooney A; Sullivan P; Sharabi Y; Goldstein DS
Neurosci Lett; 2015 Mar; 590():134-7. PubMed ID: 25637699
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
Jinsmaa Y; Isonaka R; Sharabi Y; Goldstein DS
J Pharmacol Exp Ther; 2020 Feb; 372(2):157-165. PubMed ID: 31744850
[TBL] [Abstract][Full Text] [Related]
4. DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells.
Jinsmaa Y; Sullivan P; Sharabi Y; Goldstein DS
Auton Neurosci; 2016 Jan; 194():46-51. PubMed ID: 26777075
[TBL] [Abstract][Full Text] [Related]
5. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
6. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
[TBL] [Abstract][Full Text] [Related]
7. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
[TBL] [Abstract][Full Text] [Related]
9. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.
Plotegher N; Berti G; Ferrari E; Tessari I; Zanetti M; Lunelli L; Greggio E; Bisaglia M; Veronesi M; Girotto S; Dalla Serra M; Perego C; Casella L; Bubacco L
Sci Rep; 2017 Jan; 7():40699. PubMed ID: 28084443
[TBL] [Abstract][Full Text] [Related]
10. The catecholaldehyde hypothesis: where MAO fits in.
Goldstein DS
J Neural Transm (Vienna); 2020 Feb; 127(2):169-177. PubMed ID: 31807952
[TBL] [Abstract][Full Text] [Related]
11. Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein.
Carmo-Gonçalves P; do Nascimento LA; Cortines JR; Eliezer D; Romão L; Follmer C
Biochem Biophys Res Commun; 2018 Oct; 505(1):295-301. PubMed ID: 30249394
[TBL] [Abstract][Full Text] [Related]
12. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
[TBL] [Abstract][Full Text] [Related]
13. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
[TBL] [Abstract][Full Text] [Related]
14. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
Werner-Allen JW; DuMond JF; Levine RL; Bax A
Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
[TBL] [Abstract][Full Text] [Related]
15. Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
Werner-Allen JW; Monti S; DuMond JF; Levine RL; Bax A
Biochemistry; 2018 Mar; 57(9):1462-1474. PubMed ID: 29394048
[TBL] [Abstract][Full Text] [Related]
16. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
Goldstein DS; Kopin IJ; Sharabi Y
Pharmacol Ther; 2014 Dec; 144(3):268-82. PubMed ID: 24945828
[TBL] [Abstract][Full Text] [Related]
17. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein DS
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
[TBL] [Abstract][Full Text] [Related]
18. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
[TBL] [Abstract][Full Text] [Related]
19. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by
Jinsmaa Y; Sharabi Y; Sullivan P; Isonaka R; Goldstein DS
J Pharmacol Exp Ther; 2018 Jul; 366(1):113-124. PubMed ID: 29700232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
